Cellectis revenue shrinks by about three-quarters while research outlay rises to $108.8M

Cellectis took in $14.8M of revenue in the first nine months of 2026, down from $62.6M a year earlier, a fall of roughly 76%, according to interim accounts prepared under IAS 34. Over the same period it spent $108.8M on research and development, up from $69.1M, an increase of more than half.

The two lines moved in opposite directions, leaving research costs about seven times higher than revenue. The company reported a net loss of $101.1M for the period, which it describes as wider than before. The accounts do not give the prior-year loss in the material available to us.

The balance sheet weakened over the nine months. Cellectis said its cash and current financial assets declined, though no figure for them is available to us. Shareholders' equity stood at about -$17.6M on 30 September, meaning liabilities exceeded assets on the group's reported numbers.

The full filing was not available to CompePharma, so this report cannot say what lay behind the revenue drop, which programmes drove the extra research spending, or what management said about funding and outlook. Those points need to be checked against the company's complete disclosure.